There are new warnings that the impact of the COVID pandemic on the ability to identify and treat cancer in its early stages will lead to a rise in the number of deaths.
Delegates at the annual meeting of the Radiological Society of North America (RSNA), will be told significant decreases in CT imaging for cancer have persisted even after the peak of the COVID-19 pandemic in 2020, delaying diagnosis and treatment and raising the possibility of more advanced cancers and poorer outcomes for patients in the future.
Numerous studies have shown COVID-19’s severe impact on US health care, as the pandemic filled hospitals and reduced imaging capacity during its peak of March to early May 2020. A new study has now explored the pandemic’s lingering effects on cancer imaging.
Researchers from Massachusetts General Hospital (MGH) and Harvard Medical School in Boston compared cancer-related CT exams during three periods of 2020: the pre-COVID phase (January to mid-March), peak COVID (mid-March to May) and post-COVID peak (May to mid-November). They looked at CT volume and the type of care being delivered through imaging.
As expected, CT volumes dropped significantly during the COVID peak. CT for cancer screening fell by 82%, while CT for initial workup, active cancer and cancer surveillance also saw significant declines. Volumes for cancer screening and initial workup failed to recover in the post-COVID peak period, remaining down 11.7% and 20%, respectively, from their pre-COVID numbers.
“The decline during the COVID peak was expected because of stay-at-home orders and the number of imaging departments that shut down as a precaution,” said study senior author Marc Succi, an emergency radiologist at MGH and executive director of the MESH Incubator, an in-house innovation and entrepreneurship centre. “Once normal operations resumed, you’d expect that these patients were being imaged in an equitable way, but, in fact, it turns out that they weren’t.”
The study warned the persistence of the decline in CTs for cancer screening and initial workup likely means higher numbers of patients with advanced cancers in the future.
“We expect that we’re going to see increased morbidity and mortality due to the fact that these patients weren’t able to get their routine imaging,” Succi said. “You can also surmise that they probably didn’t have their routine elective follow-up appointments as well.”
The research found CT imaging declines particularly affected the outpatient setting, as utilisation shifted away from large academic centres toward community hospitals and the Emergency Department (ED). Cancer-related CTs at the ED actually increased in the post-COVID peak period.
“The ED remains a place in the American healthcare system where people can get help, no matter the situation,” said study author Ottavia Zattra, a fourth-year medical student at Harvard Medical School. “From a systems perspective, however, the best care in terms of prevention is administered in the outpatient setting.”
The possibility of being exposed to COVID-19 likely made many cancer patients reluctant to go to large hospitals and primary care centres, the researchers said. As a result, they may have put off a visit until symptoms grew too significant to ignore.
“When initial diagnostic imaging is done in the emergency room, which suggests that people were having symptoms due to cancer for months and months, and they weren’t checking in with their primary care providers,” Zattra said. “Ultimately, the symptoms got so bad they couldn’t handle it at home.”
“We need better awareness and outreach toward the oncologic patient population,” Succi added. “For example, if a patient is due for a yearly lung cancer screening with a CT scan, we need to make sure they’re aware that they can and should get that screening regardless of COVID. Delays in screening are inevitably going to lead to delayed diagnoses and increased morbidity.”